Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts.

Autor:	Hoang TCT; Department of Pneumology, GHRMSA, Hôpital Emile Muller, Mulhouse., Debieuvre D; Department of Pneumology, GHRMSA, Hôpital Emile Muller, Mulhouse. Electronic address: debieuvred@ghrmsa.fr., Bravard AS; Department of Pneumology, CH Avranches-Granville, Granville., Martinez S; Department of Pneumology, Centre Hospitalier du Pays d'Aix, Aix-en-Provence., Le Garff G; Department of Pneumology, Centre Hospitalier de Saint-Brieuc, Saint-Brieuc., Jeandeau S; Department of Pneumology, Établissement de santé MGEN Sainte-Feyre, Sainte-Feyre., Petit L; Department of Pneumology, Centre Hospitalier Alpes-Leman, Contamine-sur-Arve., Marquette D; Department of Pneumology, Centre Hospitalier Bretagne Atlantique, Guillaudot, Vannes., Amrane K; Department of Pneumology, Centre Hospitalier des Pays de Morlaix, Morlaix., Demontrond P; Department of Pneumology, Centre François Baclesse, Caen., Tiercin M; Department of Pneumology, Centre Hospitalier de Saint-Malo, Saint-Malo., Jarjour B; Department of Pneumology, Centre Hospitalier de Béziers, Béziers., Turlotte A; Department of Pneumology, Centre Hospitalier d'Arras, Arras., Masson P; Department of Pneumology, Centre Hospitalier de Cholet, Cholet., Jaafar M; Department of Pneumology, Centre Hospitalier Eure-Seine, Évreux., Hauss PA; Department of Pneumology, CHI Elbeuf Louviers Val de Reuil, Saint-Aubin-lès-Elbeuf., Morel H; Department of Pneumology, Centre Hospitalier Régional D'orléans, Hôpital de La Source, Orléans, France.
Jazyk:	angličtina
Zdroj:	ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103594. Date of Electronic Publication: 2024 Jun 07.
DOI:	10.1016/j.esmoop.2024.103594
Abstrakt:	Background: The impact of the most recent advances, including targeted therapies and immune checkpoint inhibitors, on early (3-month) mortality in lung cancer is unknown. The aims of this study were to evaluate the real-world rate of and risk factors for early mortality, as well as trends in early mortality over the last 20 years. Materials and Methods: The KBP prospective observational multicenter studies have been conducted every 10 years since 2000. These studies collect data on all newly diagnosed patients with lung cancer (all stages and histologies) over 1 year in non-academic public hospital pulmonology or oncology units in France. In this study, we analyzed data on patient and tumor characteristics from participants in the KBP-2020 cohort and compared the characteristics of patients who died within 3 months of diagnosis with those of all other patients within the cohort. We also carried out a comparative analysis with the KBP-2000 and KBP-2010 cohorts. Results: Overall, 8999 patients from 82 centers were included in the KBP-2020 cohort. Three-month survival data were available for 8827 patients, of whom 1792 (20.3%) had died. Risk factors for early mortality were: male sex, age >70 years, symptomatic disease at diagnosis, ever smoker, weight loss >10 kg, poor Eastern Cooperative Oncology Group performance status (≥1), large-cell carcinoma or not otherwise specified, and stage ≥IIIC disease. The overall 3-month mortality rate was found to have decreased significantly over the last 20 years, from 24.7% in KBP-2000 to 23.4% in KBP-2010 and 20.3% in KBP-2020 (P < 0.0001). Conclusion: Early mortality among patients with lung cancer has significantly decreased over the last 20 years which may reflect recent improvements in treatments. However, early mortality remained extremely high in 2020, particularly when viewed in light of improvements in longer-term survival. Delays in lung cancer diagnosis and management could contribute to this finding. Competing Interests: Disclosure The authors have declared no conflicts of interest. (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu